Australia - englanti - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 17.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 15 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 12.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 7.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Australia - englanti - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 1.25 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 1.32 mg/ml); fentanyl citrate, quantity: 7.9 microgram/ml (equivalent: fentanyl, qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - marcain 0.125% with fentanyl is intended for post-operative or obstetric epidural analgesia.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: povidone; sodium lauryl sulfate; saccharin sodium; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; maize starch; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: saccharin sodium; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; povidone; magnesium stearate; maize starch; lactose monohydrate; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.